Restenosis in the SFA
Due to the biological environment and significant mechanical forces in the SFA, the timing of restenosis is longer than in other anatomies. As a result, engineers for the Eluvia Drug-Eluting Stent needed to identify the right formulation of paclitaxel and polymer to tune an elution curve that would help ensure the drug is available when restenosis is most likely to occur.
Clinical History of Restenosis1
Sustained Drug Release Beyond 12 Months
The Eluvia Drug-Eluting Stent is the only therapy for the SFA designed to match the release of paclitaxel to the restenotic process for better healing and patency.
- Iida, O. et al. Catheterization and Cardiovascular Interventions. 2011; 78:611–617.
- Based on preclinical pharmacokinetic analysis for Zilver PTX. Dake MD, et al. J Vasc Interv Radiol. 2011;22(5):603-610.
- Based on preclinical pharmacokinetic analysis for three Drug-Coated Balloons (IN.PACT Pacific, Lutonix, Ranger). Gongora CA, et al. JACC Cardiovasc Interv. 2015 Jul;8(8):1115-1123. doi: 10.1016/j.jcin.2015.03.020.
- Based on preclinical pharmacokinetic analysis for Eluvia. Data on file at Boston Scientific.
Designed for Better Patient Outcomes
Stent Design & Delivery
Built on the foundation of the next-generation Innova™ Stent platform, the Eluvia Drug-Eluting Stent is designed to provide uniform scaffolding for drug delivery while optimizing flexibility, radial strength and fracture resistance.
Stay Up to Date
Receive emails about the latest drug-eluting technology news, innovations and events in your area.
Explore DE Resources
Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.